Initial Public Offering
Baird served as co-lead manager on this offering
AboutDicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ-GS: DRNA) recently completed an initial public offering of 6,900,000 shares of common stock at a price of $15.00 per share, generating gross proceeds of $103.5 million. The Company intends to use the net proceeds from the offering to fund preclinical studies and clinical trials for DCR- PH1, DCR- M1711 and another liver target to be advanced into development.
Dicerna is a biopharmaceutical company focused on the discovery and development of treatments for rare inherited disease involving the liver and for cancers that are genetically defined. Dicerna is using proprietary RNA interference (RNAi) technology platform, which the Company believes improves on existing RNAi technologies, to build a broad pipeline in these therapeutic areas. Dicerna intends to discover, develop and commercialize novel therapeutics either on the Company’s own or in collaboration with pharmaceutical partners. Dicerna is headquartered in Watertown, Massachusetts.
For additional information about this transaction, please contact:
- January 2014
- Dicerna Pharmaceuticals, Inc.
- Target Location
- North America